What is HC Wainwright’s Estimate for ABEO FY2024 Earnings?

Abeona Therapeutics Inc (NASDAQ:ABEO) – Stock analysts at HC Wainwright lifted their FY2024 EPS estimates for Abeona Therapeutics in a report released on Monday, November 25th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of ($1.16) for the year, up from their previous estimate of ($1.26). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.17) EPS.

Other equities research analysts have also issued reports about the stock. StockNews.com raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

Abeona Therapeutics Trading Up 1.5 %

Shares of NASDAQ:ABEO opened at $6.03 on Wednesday. The stock has a 50 day moving average of $6.21 and a 200 day moving average of $5.30. The company has a market cap of $262.13 million, a PE ratio of -2.24 and a beta of 1.52. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $9.01. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ABEO. Rosalind Advisors Inc. purchased a new stake in Abeona Therapeutics during the 2nd quarter valued at approximately $7,420,000. Renaissance Technologies LLC grew its holdings in Abeona Therapeutics by 581.6% during the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after buying an additional 429,456 shares in the last quarter. Simplify Asset Management Inc. purchased a new stake in Abeona Therapeutics during the 2nd quarter valued at approximately $1,732,000. abrdn plc grew its holdings in Abeona Therapeutics by 158.8% during the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after buying an additional 200,647 shares in the last quarter. Finally, Western Standard LLC grew its holdings in Abeona Therapeutics by 7.0% during the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after buying an additional 110,998 shares in the last quarter. 80.56% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.